The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics.
Lelong M, Josien R, Coste-Burel M, Rimbert M, Bressollette-Bodin C, Nancey S, Bouguen G, Allez M, Serrero M, Caillo L, Rouillon C, Blanc P, Laharie D, Olivier R, Peyrin-Biroulet L, Dib N, De Maissin A, Montuclard C, Trang-Poisson C, Vavasseur F, Gallot G, Berthome M, Braudeau C, Chevreuil J, Bourreille A, Le Berre C.
Lelong M, et al. Among authors: coste burel m.
Front Immunol. 2023 Aug 28;14:1243898. doi: 10.3389/fimmu.2023.1243898. eCollection 2023.
Front Immunol. 2023.
PMID: 37701431
Free PMC article.